Associated Papers
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT et al.
The Lancet. Oncology, 2017
29074098 (PubMed )
Supplement: NIHMS930149-supplement.pdf
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
Lin YT et al.
Clinical Lung Cancer, 2016
Select a paper to view details